Methods and systems for presenting a combination treatment
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G06F-019/00
G06Q-050/22
G06Q-050/24
출원번호
US-0290456
(2008-10-29)
등록번호
US-9026369
(2015-05-05)
발명자
/ 주소
Hyde, Roderick A.
Ishikawa, Muriel Y.
Leuthardt, Eric C.
Levien, Royce A.
Lord, Robert W.
Malamud, Mark A.
Sweeney, Elizabeth A.
Wood, Jr., Lowell L.
Wood, Victoria Y. H.
출원인 / 주소
The Invention Science Fund I, LLC
인용정보
피인용 횟수 :
3인용 특허 :
89
초록▼
Methods, computer program products, and systems are described that include accepting an indication of an individual's compliance with an artificial sensory experience and presenting an indication of a bioactive agent at least partly based on the indication of the individual's compliance with the art
Methods, computer program products, and systems are described that include accepting an indication of an individual's compliance with an artificial sensory experience and presenting an indication of a bioactive agent at least partly based on the indication of the individual's compliance with the artificial sensory experience.
대표청구항▼
1. A system comprising: circuitry configured to accept an indication of usage by an individual of an artificial sensory experience; andcircuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory exper
1. A system comprising: circuitry configured to accept an indication of usage by an individual of an artificial sensory experience; andcircuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience. 2. The system of claim 1, wherein the circuitry configured to accept an indication of usage by an individual of an artificial sensory experience comprises: circuitry configured to accept an indication of usage by an individual of a prescribed artificial sensory experience. 3. The system of claim 1, wherein the circuitry configured to accept an indication of usage by an individual of an artificial sensory experience comprises: circuitry configured to accept a self-report of usage by an individual of an artificial sensory experience. 4. The system of claim 1, wherein the circuitry configured to accept an indication of usage by an individual of an artificial sensory experience comprises: circuitry configured to accept an indication from a health care provider of usage by an individual of an artificial sensory experience. 5. The system of claim 1, wherein the circuitry configured to accept an indication of usage by an individual of an artificial sensory experience comprises: circuitry configured to accept a report from an artificial sensory experience provider of usage by an individual of an artificial sensory experience. 6. The system of claim 1, wherein the circuitry configured to accept an indication of usage by an individual of an artificial sensory experience comprises: circuitry configured to accept an indication of usage by an individual of a virtual world. 7. The system of claim 1, wherein the circuitry configured to accept an indication of usage by an individual of an artificial sensory experience comprises: circuitry configured to accept an indication of interaction by an individual with an artificial sensory experience. 8. The system of claim 1, wherein the circuitry configured to accept an indication of usage by an individual of an artificial sensory experience comprises: circuitry configured to accept an indication of presence by an individual with respect to an artificial sensory experience. 9. The system of claim 1, further comprising: circuitry configured to accept a physiological measurement. 10. The system of claim 1, further comprising: circuitry configured to monitor a parameter. 11. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present an indication of a prescription bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience. 12. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present in near real-time an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience. 13. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present an indication of a bioactive agent and a side effect at least partly based on the indication of usage by the individual of the artificial sensory experience. 14. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present an indication of a bioactive agent at least partly based on an algorithm. 15. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience module comprises: circuitry configured to present an indication of a bioactive agent at least partly based on a comparison. 16. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present an indication of a bioactive agent at least partly based on a matching algorithm. 17. The system of claim 1, further comprising: circuitry configured for determining the bioactive agent. 18. The system of claim 1, further comprising: an output device. 19. The system of claim 1, further comprising: a user interface. 20. The system of claim 1, further comprising: a mobile device. 21. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present to a third party an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience. 22. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present to a health care provider an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience. 23. The system of claim 1, further comprising: circuitry configured to compare a physiological parameter value detected during usage by the individual of the artificial sensory experience with an expected physiological parameter value. 24. The system of claim 23, further comprising: circuitry configured to determine the bioactive agent based at least partly on the physiological parameter value detected during usage by the individual of the artificial sensory experience being other than the expected physiological parameter value. 25. The system of claim 24, wherein the circuitry configured to determine the bioactive agent based at least partly on the physiological parameter value detected during usage by the individual of the artificial sensory experience being other than the expected physiological parameter value comprises: circuitry configured to determine the bioactive agent (i) based at least partly on the physiological parameter value detected during usage by the individual of the artificial sensory experience being other than the expected physiological parameter value and (ii) based at least partly on a genetic profile of the individual. 26. The system of claim 1, further comprising: circuitry configured to monitor computer usage history associated with an individual with respect to a social networking application;circuitry configured to determine that the individual is prone to depression based at least partly on the computer usage history associated with the individual with respect to the social networking application; andcircuitry configured to modify a user interface of the social networking application with respect to the individual based at least partly on a determination that the individual is prone to depression,wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises circuitry configured to present an indication of an anti-depressant bioactive agent that is configured to reduce depression. 27. The system of claim 1, further comprising: circuitry configured to present the artificial sensory experience that includes an fear-inducing virtual world aspect;circuitry configured to monitor an appearance of the individual in association with presentation of the artificial sensory experience that includes the fear-inducing virtual world aspect;circuitry configured to determine an anti-anxiety bioactive agent and a dosage of the anti-anxiety bioactive agent based at least partly on the monitored appearance of the individual; andcircuitry configured to modify an aspect of the artificial sensory experience based at least partly on the monitored appearance of the individual. 28. The system of claim 1, further comprising: circuitry configured to monitor computer usage history associated with an individual with respect to a game application;circuitry configured to determine that the individual is prone to mania based at least partly on the computer usage history associated with the individual with respect to the game application; andwherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises circuitry configured to present an indication of an anti-manic bioactive agent that is configured to reduce mania. 29. The system of claim 1, wherein the circuitry configured to accept an indication of usage by an individual of an artificial sensory experience comprises: circuitry configured to accept a usage score of an individual with respect to an artificial sensory experience. 30. The system of claim 1, wherein the circuitry configured to accept an indication of usage by an individual of an artificial sensory experience comprises: circuitry configured to accept an indication motion detected using one or more motion sensors. 31. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present to a computing device an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience. 32. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present an indication of an anti-depressant agent at least partly based on the indication of usage by the individual of the artificial sensory experience. 33. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present an indication of an anti-anxiety agent at least partly based on the indication of usage by the individual of the artificial sensory experience. 34. The system of claim 1, wherein the circuitry configured to present an indication of a bioactive agent at least partly based on the indication of usage by the individual of the artificial sensory experience comprises: circuitry configured to present an indication of an anti-psychotic agent at least partly based on the indication of usage by the individual of the artificial sensory experience.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (89)
Auer,John A.; Rutledge,Jolyn; Monteleone,Rand J., Apparatus for processing and displaying patient medical information.
Birkner, Charles Christian; ElDahdah, Elias George; Kirkland, Heather Ann; Martinez, David Frederick, Computerized laboratory information management system.
Oshlack Benjamin (New York NY) Chasin Mark (Manalpan NJ) Minogue John J. (Mount Vernon NY) Kaiko Robert F. (Weston CT), Controlled release oxycodone compositions.
Suffin,Stephen C.; Emory,W. Hamlin; Brandt,Leonard J., Electroencephalography based systems and methods for selecting therapies and predicting outcomes.
Kehr Bruce A. (9429 Holbrook La. Potomac MD 20854) Lerner David (New York NY) Demenus Richard D. (New York NY) Edl Michael J. (New York NY), Electronic medication dispensing method.
Gerald E. Goetz ; Terry Precht ; Eric Krug ; Andrew Fanton ; Joe Keating ; Brian Coppom ; Bradley Thompson ; Brian Hepp, Medication monitoring system and apparatus.
Geerts, Hugo; Spiros, Athan, Method and apparatus for computer modeling of the interaction between and among cortical and subcortical areas in the human brain for the purpose of predicting the effect of drugs in psychiatric and cognitive diseases.
Christopher J. Frederickson ; Donald J. Hayes ; David B. Wallace ; David W. Taylor ; Matthew D. Hayes, Method and apparatus for delivery of fragrances and vapors to the nose.
Miller Steven L. ; Merzenich Michael M. ; Peterson Bret E., Method and apparatus for dynamically tailoring biochemical based therapy programs in human.
Webster Henry L. ; Barlow Wayne K. ; Briscoe Dennis R. ; Quirante Carmelo G. ; Thomas Scot B., Method and system for continuous sweat collection and analysis.
Leamon, John H.; McDade, Keith E.; Fierro, Joseph M.; Knight, James R.; Charumilind, Jaran; Myers, Jr., Eugene W.; Simpson, John W.; Volkmer, Greg A., Methods of amplifying and sequencing nucleic acids.
Lloyd Harry A. (11101 Sweetwood La. Oakton VA 22124) Jones Timothy (17 Court St. P.O. Box 160 Windsor VA 23487) Dunn Dan C. (23 Hearthstone Rd. Monroe CT 06468), Portable electronic medication dosage instruction and alarm device.
Thrall Karla D. (3804 Alder Lake Ct. West Richland WA 99353) Kenny Donald V. (6947 Sparrow La. Worthington OH 43235) Endres George W. R. (2112 Briarwood Ct. Richland WA 99352) Sisk Daniel R. (1211 Ma, Real time chemical exposure and risk monitor.
Agrafiotis Dimitris K. (Exton PA) Bone Roger F. (Bridgewater NJ) Salemme Francis R. (Kennett Square PA) Soll Richard M. (Lawrenceville NJ), System and method of automatically generating chemical compounds with desired properties.
Patton David L. ; Fredlund John R. ; Horwitz Cecelia M. ; Mir Jose M., System and method of managing a psychological state of an individual using images.
Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Combination treatment selection methods and systems.
Jung, Edward K. Y.; Leuthardt, Eric C.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Wood, Jr., Lowell L., Methods and systems for indicating behavior in a population cohort.
Jung, Edward K. Y.; Leuthardt, Eric C.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Wood, Jr., Lowell L., Population cohort-linked avatar.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.